Video Experimental Relacionado
Updated: Sep 10, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.2K
Pityriasis rubra pilaris refractaria tratada con abrocitinib
1Department of Dermatovenerology, Second Faculty of Medicine, Charles University, Bulovka University Hospital, Prague.
Dermatology reports
|August 22, 2025
Resumen
La pitiriasis rubra pilaris (PRP) es una enfermedad cutánea rara. Este estudio de caso muestra un tratamiento exitoso del PRP refractario con abrocitinib, un inhibidor de JAK1, cuando otras terapias fallaron.
Área de la Ciencia:
- Dermatología
- Inmunología
- Farmacología
Sus antecedentes:
- La pitiriasis rubra pilaris (PRP) es un trastorno papulosquamo raro.
- El PRP tiene un impacto significativo en la calidad de vida del paciente.
- El PRP es a menudo refractario a los tratamientos convencionales.
Objetivo del estudio:
- Para presentar un caso de tratamiento PRP exitoso.
- Evaluar la eficacia del abrocitinib en un caso de PRP refractario.
Principales métodos:
- Se utilizó un enfoque de estudio de casos.
- El tratamiento incluyó abrocitinib, un inhibidor de Janus kinase 1 (JAK1).
- Las terapias convencionales y biológicas anteriores habían fracasado.
Principales resultados:
- El paciente experimentó un tratamiento exitoso con abrocitinib.
- Abrocitinib demostró eficacia en un paciente con PRP resistente al tratamiento.
Conclusiones:
- El abrocitinib puede ser una opción terapéutica viable para la pitiriasis rubra pilaris refractaria.
- La orientación de JAK1 con abrocitinib es prometedora para el tratamiento de casos graves de PRP.
Videos de Conceptos Relacionados
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
267
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
01:29Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
202
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
202
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
252
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
252
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
231
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231